Cargando…

A confidence function‐based posterior probability design for phase II cancer trials

Single‐arm one‐ or multi‐stage study designs are commonly used in phase II oncology development when the primary outcome of interest is tumor response, a binary variable. Both two‐ and three‐outcome designs are available. Simon two‐stage design is a well‐known example of two‐outcome designs. The obj...

Descripción completa

Detalles Bibliográficos
Autor principal:	Shan, Minghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Main Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246966/ https://www.ncbi.nlm.nih.gov/pubmed/33336856 http://dx.doi.org/10.1002/pst.2089

Ejemplares similares

SCI: A Bayesian adaptive phase I/II dose‐finding design accounting for semi‐competing risks outcomes for immunotherapy trials
por: Zhang, Yifei, et al.
Publicado: (2022)

A novel equivalence probability weighted power prior for using historical control data in an adaptive clinical trial design: A comparison to standard methods
por: Bennett, Maxine, et al.
Publicado: (2021)

Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data
por: Kunz, Cornelia Ursula, et al.
Publicado: (2014)

CUSUMIN: A cumulative sum interval design for cancer phase I dose finding studies
por: Hatayama, Tomoyoshi, et al.
Publicado: (2022)

Practical and robust test for comparing binomial proportions in the randomized phase II setting
por: Attwood, Kristopher, et al.
Publicado: (2021)

Escalation strategies for combination therapy Phase I trials
por: Sweeting, Michael J, et al.
Publicado: (2012)

An optimal stratified Simon two‐stage design
por: Parashar, Deepak, et al.
Publicado: (2016)

Do single‐arm trials have a role in drug development plans incorporating randomised trials?
por: Grayling, Michael J., et al.
Publicado: (2015)

Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology
por: Ristl, Robin, et al.
Publicado: (2020)

Potential impact of COVID‐19 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Severity Scale based on the CANNA‐TICS study
por: Lasch, Florian, et al.
Publicado: (2021)

Response‐adaptive designs for binary responses: How to offer patient benefit while being robust to time trends?
por: Villar, Sofía S., et al.
Publicado: (2017)

A critical review of graphics for subgroup analyses in clinical trials
por: Ballarini, Nicolás M., et al.
Publicado: (2020)

Blinded continuous monitoring in clinical trials with recurrent event endpoints
por: Friede, Tim, et al.
Publicado: (2018)

Should the two‐trial paradigm still be the gold standard in drug assessment?
por: Zhan, Stella Jinran, et al.
Publicado: (2022)

Optimal composite scores for longitudinal clinical trials under the linear mixed effects model
por: Ard, M. Colin, et al.
Publicado: (2015)

Assessing efficacy in important subgroups in confirmatory trials: An example using Bayesian dynamic borrowing
por: Best, Nicky, et al.
Publicado: (2021)

Decision rules for identifying combination therapies in open‐entry, randomized controlled platform trials
por: Meyer, Elias Laurin, et al.
Publicado: (2022)

Incorporating historical controls in clinical trials with longitudinal outcomes using the modified power prior
por: Qi, Hongchao, et al.
Publicado: (2022)

Prior distributions for variance parameters in a sparse‐event meta‐analysis of a few small trials
por: Pateras, Konstantinos, et al.
Publicado: (2020)

Imputation of missing covariate in randomized controlled trials with a continuous outcome: Scoping review and new results
por: Kayembe, Mutamba T., et al.
Publicado: (2020)

A review and re-interpretation of a group-sequential approach to sample size re-estimation in two-stage trials
por: Bowden, J, et al.
Publicado: (2014)

A compassionate imagery intervention for patients with persecutory delusions
por: Forkert, Ava, et al.
Publicado: (2022)

Cognitive appraisals of dissociation in psychosis: a new brief measure
por: Černis, Emma, et al.
Publicado: (2021)

Are young people with primary social anxiety disorder less likely to recover following generic CBT compared to young people with other primary anxiety disorders? A systematic review and meta-analysis
por: Evans, Rachel, et al.
Publicado: (2021)

Understanding agoraphobic avoidance: the development of the Oxford Cognitions and Defences Questionnaire (O-CDQ)
por: Rosebrock, Laina, et al.
Publicado: (2022)

Empirical evaluation of the implementation of the EMA guideline on missing data in confirmatory clinical trials: Specification of mixed models for longitudinal data in study protocols
por: Häckl, Sebastian, et al.
Publicado: (2019)

Standard and reference‐based conditional mean imputation
por: Wolbers, Marcel, et al.
Publicado: (2022)

Reference‐based sensitivity analysis for time‐to‐event data
por: Atkinson, Andrew, et al.
Publicado: (2019)

Development of a scale for capturing psychological aspects of physical–digital integration: relationships with psychosocial functioning and facial emotion recognition
por: Colledani, Daiana, et al.
Publicado: (2023)

Estimation of treatment effects in short‐term depression studies. An evaluation based on the ICH E9(R1) estimands framework
por: Mitroiu, Marian, et al.
Publicado: (2022)

Design of Phase II cancer trials evaluating survival probabilities
por: Case, L Douglas, et al.
Publicado: (2003)

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022)

Burden‐of‐illness vaccine efficacy
por: Callegaro, Andrea, et al.
Publicado: (2020)

Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies
por: Austin, Peter C
Publicado: (2011)

Why are two mistakes not worse than one? A proposal for controlling the expected number of false claims
por: Jaki, Thomas, et al.
Publicado: (2016)

A proposal for a new PhD level curriculum on quantitative methods for drug development
por: Jaki, T., et al.
Publicado: (2018)

Dose‐escalation strategies which use subgroup information
por: Cotterill, Amy, et al.
Publicado: (2018)

On estimands and the analysis of adverse events in the presence of varying follow‐up times within the benefit assessment of therapies
por: Unkel, Steffen, et al.
Publicado: (2018)

Α Markov model for longitudinal studies with incomplete dichotomous outcomes
por: Efthimiou, Orestis, et al.
Publicado: (2016)

Misspecification of at‐risk periods and distributional assumptions in estimating COPD exacerbation rates: The resultant bias in treatment effect estimation
por: Law, M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gv1nbe8sgkec36in013hija5fv